Biophytis Announces 2022 Financial Results and 2023 Perspectives

  • €11.1M of available cash and equivalents on December 31, 2022, and financing instruments for a total of €22M allowing financial visibility beyond mid 2024
  • Positive results of the Phase 2-3 COVA study for the treatment of severe COVID-19 with Sarconeos (BIO101)
  • Early Access Program (EAP) submission in France by June 2023 while preparing filing for conditional marketing authorization in the USA and Europe for Sarconeos (BIO101) in COVID-19